Discipline **MCP5860**  
**The Role of Bariatric Surgery and Incretin Hormones in Diabetes, Metabolic Syndrome and Cardiovascular Risk**

**Concentration area:** 5131  
**Creation:** 13/12/2016  
**Activation:** 13/12/2016  
**Credits:** 2  
**Workload:**

<table>
<thead>
<tr>
<th>Theory (weekly)</th>
<th>Practice (weekly)</th>
<th>Study (weekly)</th>
<th>Duration</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>10</td>
<td>10</td>
<td>1 weeks</td>
<td>30 hours</td>
</tr>
</tbody>
</table>

**Professor:**  
Bruno Caramelli

**Objectives:**

1. Provide new knowledge on bariatric surgery and incretin hormones modulation and their impact on metabolism and cardiovascular risk reduction.  
2. Discuss the effectiveness of treatments available today for obesity and metabolic syndrome.  
3. Foster the discussion about the importance of investigating new treatments for metabolic conditions, which increase cardiovascular risk.  
4. Discuss research methodology (outcomes, criteria, variables) in this area of knowledge.

**Rationale:**

Bariatric surgery is considered today a very efficient treatment option in the control and correction of metabolic disorders related to obesity and overweight. This modality of treatment has advantages over other available strategies (pharmacological treatment and lifestyle change) while it causes definitive and profound changes in the body of the sick individuals. There is still no consensus regarding the efficacy of this treatment when it comes to cardiovascular risk reduction, however many studies are being conducted with quite expressive results. Hence, we gather a group of renowned scientists on this field to encourage discussion on the issue and stimulate further research regarding this topic so current. International guest researchers have extensive experience in the investigation of diabetes mellitus, metabolic syndrome and new treatments for these conditions. By combining the expertise of all these high-level researchers with extensive experience in the area, it will be possible to create an extremely rich and complete lecture in this new and promising field. All invited guests act in similar but complementary areas.

**Content:**

First Day: 1. Bariatric Surgery – History and Surgical procedure Details.  
2. Clinical Treatment of Obesity – Have we reached the limit?  
3. Which intervention is suitable for which patient?  
4. Physiopathological principles of Bariatric Surgery  
Second Day: 5. Gut, Diabetes and Obesity  
New aspects in the clinical treatment of obesity  
Obesity and Metabolic Syndrome  
Epicardial Fat  
Potential impact of bariatric surgery on cancer incidence  
7. Is Metabolic Surgery the right treatment for DM2?  
**Type of Assessment:**
Attending the sessions and written evaluation of the course.

**Notes/Remarks:**

The international guest researchers to attend and present sessions during the course are the following: - Frida Leonetti, M.D. PhD is a clinical endocrinologist and researcher affiliated with the University "La Sapienza" in Rome, Italy. Her main investigation is focused in type 2 Diabetes and Metabolic Syndrome. Recently she concentrated in the study of surgical procedures for the treatment of type 2 Diabetes in obese individuals, publishing several articles in major journals, such as Archives of Surgery. Her scientific production is rich and extensive, represented by an index H of 23. Her ample experience in leading clinical trials evaluating the impact of bariatric surgery in diabetic patients, especially with sleeve gastrectomy, is of great value to the students whose thesis involves cardiovascular risk. Finally, Dr. Frida is part of a thematic project ( FAPESP 10 / 198927-4 ) of this institution as an associated researcher. - Giuseppe Barbaro, MD, is specialist in Internal Medicine and Cardiology. He is Assistant Professor of Medicine and Chief of Cardiology Unit, Department of Medical Pathophysiology, University of Rome "La Sapienza". He is an active member of several National and International Societies of Internal Medicine and Cardiology (including the European Society of Cardiology and the Clinical Council of the American Heart Association) and Fellow of the American College of Chest Physicians (FCCP) and of the Royal Society of Medicine (FRS). He is also the principal Author of more than 200 scientific publications, including clinical reviews, original papers on national and international journals, chapters in textbooks and presentations at Scientific Meetings, regarding different clinical and therapeutic aspects in Internal Medicine, Emergency Medicine and Cardiology. His current field of clinical investigation regards the study of new markers of visceral obesity, and related cardiovascular risk, in HIV-infected subjects with lipodistrophy syndrome as well as in HIV-uninfected subjects with obesity and metabolic syndrome. - GELTRUDE MINGRONE, M.D. PhD is a clinical endocrinology with Board Certified in Gastroenterology; Diabetology and Metabolic Diseases; and Forensic Medicine. She is an Associate Professor at the Department of internal medicine and the Head of the Division of Obesity and Metabolic Disorders at the Catholic University of Rome (Italy). Beyond practicing medicine, Dr. Mingrone also has a sincere interest in medical research, particularly in the diabetes field. In addition to being one of the leader investigators for lipid and carbohydrate metabolism, Dr. Mingrone has a faculty appointment in the Department of internal medicine of the Catholic University in Rome. Also Dr. Mingrone has written more than 250 peer-reviewed publications with a global impact factor of about 1000.

**Bibliography:**


